• #22: Glatiramer Acetate : Anaphylaxis Risk and Warnings

  • Feb 11 2025
  • Length: 4 mins
  • Podcast

#22: Glatiramer Acetate : Anaphylaxis Risk and Warnings

Listen for free

View show details

  • Summary

  • The FDA is alerting the public to the risk of anaphylaxis, a rare but serious allergic reaction, associated with glatiramer acetate (Copaxone, Glatopa), a drug used to treat multiple sclerosis (MS). Anaphylaxis can occur at any time during treatment, even after doses administered months or years after starting the medicine, and has sometimes resulted in hospitalization and death. Symptoms typically appear within one hour of injection.

    To communicate this risk, the FDA is adding a Boxed Warning to the prescribing information and patient Medication Guide. Patients should stop taking glatiramer acetate and seek immediate medical attention if they experience symptoms of anaphylaxis such as wheezing, difficulty breathing, swelling of the face, lips, or throat, or hives. While early symptoms of anaphylaxis can be similar to a temporary post-injection reaction, they are typically more severe and worsen over time. If symptoms are more than mild, worsen, or do not go away quickly, patients should seek immediate medical attention


    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less

What listeners say about #22: Glatiramer Acetate : Anaphylaxis Risk and Warnings

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available